Background Neonatal abstinence syndrome (NAS) occurs following prenatal opioid
exposure. It is characterized by signs and symptoms indicating central nervous system …

The Opioid Neonatal Abstinence Syndrome (NAS) is a term used to describe a cluster of
signs and symptoms seen in infants experiencing withdrawal from opioid drugs. Despite a …

The infant exposed to opioids in utero frequently presents a challenge to the neonatal care
provider in the assessment and treatment of symptoms of Neonatal Abstinence Syndrome …

Chronic intrauterine exposure to psychoactive drugs often results in neonatal opioid
withdrawal syndrome (NOWS). When nonpharmacologic measures are insufficient in …

Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

Background: The evaluation and management of infants with neonatal abstinence syndrome
(NAS), the constellation of opioid withdrawal specific to newborns, have received renewed …

The management of the infant exposed to drugs in utero poses significant challenges.
Symptoms and signs of neonatal abstinence syndrome (NAS) are non-specific but most …

Neonatal abstinence syndrome (NAS) is defined as a constellation of symptoms typically
observed in the newborn of a mother who has received opioids and other medications for a …

Perinatal opioid misuse and neonatal opioid withdrawal syndrome (NOWS) are a significant
public health problem that has grown exponentially over the past decade. In the United …

Background: Twenty percent to 40% of infants exposed to in utero opioid were delivered
preterm. There is currently no neonatal abstinence syndrome (NAS) scoring tool known to …